# OnCo record adc (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/adc/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "adc" ;
  schema:name "Antibody-drug conjugate (ADC)"@en ;
  schema:description "An antibody-drug conjugate is an antibody that homes to a protein on the tumour cell, is swallowed, and releases a chemotherapy payload inside it. That widens chemotherapy's safe dose window about a hundredfold, which is why payloads too toxic to give alone can be used, though lung inflammation, neutropenia and eye toxicity from the payload still occur."@en ;
  schema:url <https://onco.cc/technologies/adc/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Antibody-drug_conjugate> ;
  schema:citation <https://en.wikipedia.org/wiki/Antibody-drug_conjugate> ;
  onco:status "approved" ;
  onco:related <https://onco.cc/ideas/idea-efflux-agnostic/>, <https://onco.cc/ideas/idea-neoadjuvant-adc-io/> ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/adcs/> ;
  onco:technologies <https://onco.cc/technologies/topoisomerase-inhibitors/>, <https://onco.cc/technologies/bispecific-adc/>, <https://onco.cc/technologies/dual-payload-adc/>, <https://onco.cc/technologies/degrader-antibody-conjugate/>, <https://onco.cc/technologies/immune-stimulating-adc/>, <https://onco.cc/technologies/masked-adc/>, <https://onco.cc/technologies/site-specific-conjugation/>, <https://onco.cc/technologies/radioimmunotherapy/> ;
  onco:targets <https://onco.cc/targets/trop2/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/her3/>, <https://onco.cc/targets/nectin4/>, <https://onco.cc/targets/b7h3/>, <https://onco.cc/targets/cldn18-2/>, <https://onco.cc/targets/folr1/>, <https://onco.cc/targets/tissue-factor/>, <https://onco.cc/targets/cdh6/>, <https://onco.cc/targets/met/>, <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/bcma/>, <https://onco.cc/targets/cd33/>, <https://onco.cc/targets/cd123/>, <https://onco.cc/targets/ror1/>, <https://onco.cc/targets/cd79b/>, <https://onco.cc/targets/cd30/>, <https://onco.cc/targets/cd22/> ;
  onco:companies <https://onco.cc/companies/celldex/>, <https://onco.cc/companies/tubulis/>, <https://onco.cc/companies/adcendo/>, <https://onco.cc/companies/alentis-therapeutics/>, <https://onco.cc/companies/bighat-biosciences/>, <https://onco.cc/companies/callio-therapeutics/>, <https://onco.cc/companies/cytomx-therapeutics/>, <https://onco.cc/companies/dantari/>, <https://onco.cc/companies/emergence-therapeutics/>, <https://onco.cc/companies/enlaza-therapeutics/>, <https://onco.cc/companies/firefly-bio/>, <https://onco.cc/companies/ideaya-biosciences/>, <https://onco.cc/companies/iksuda-therapeutics/>, <https://onco.cc/companies/mablink-bioscience/>, <https://onco.cc/companies/myricx-bio/>, <https://onco.cc/companies/mythic-therapeutics/>, <https://onco.cc/companies/nbe-therapeutics/>, <https://onco.cc/companies/orum-therapeutics/>, <https://onco.cc/companies/pheon-therapeutics/>, <https://onco.cc/companies/profoundbio/>, <https://onco.cc/companies/tallac-therapeutics/>, <https://onco.cc/companies/valink-therapeutics/> ;
  onco:terms <https://onco.cc/terms/payload/>, <https://onco.cc/terms/linker/>, <https://onco.cc/terms/dar/>, <https://onco.cc/terms/bystander-effect/>, <https://onco.cc/terms/ild/> ;
  onco:trials <https://onco.cc/trials/aaml0531/>, <https://onco.cc/trials/luminosity/>, <https://onco.cc/trials/nct07299747/>, <https://onco.cc/trials/nct06797999/>, <https://onco.cc/trials/nct06842498/>, <https://onco.cc/trials/nct07354711/>, <https://onco.cc/trials/nct07258407/>, <https://onco.cc/trials/nct06464055/> ;
  onco:dependsOn <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/adc-cdmo-manufacturing/>, <https://onco.cc/technologies/high-potency-payload-synthesis/>, <https://onco.cc/technologies/site-specific-conjugation/>, <https://onco.cc/technologies/sterile-fill-finish/> .